STK11 and neoplasm: More importantly, JOSD2 distinctly accelerated the in vivo tumor growth in NCI-H460 xenografted tumors harboring LKB1-WT, but exerting minimal impact in control and LKB1-3KR groups (Fig. 5h–j).